A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2019
Price : $35 *
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AbbVie
- 29 Aug 2019 Status changed from recruiting to discontinued.According to an AbbVie media release, the company discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
- 23 May 2019 Planned number of patients changed from 80 to 20.
- 20 Dec 2018 Planned End Date changed from 30 Aug 2023 to 5 Feb 2024.